- Home
- KURA vs LENZ Comparison
KURA vs LENZ Comparison
Compare KURA & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$8.95
HOLD
Current Price
$11.66
Company Overview
Basic Information| Metric | KURA | LENZ |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.0M | 609.5M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KURA | LENZ |
|---|---|---|
| Price | $8.95 | $11.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $26.88 | ★ $56.25 |
| AVG Volume (30 Days) | ★ 1.5M | 731.1K |
| Earning Date | 05-28-2026 | 04-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,482,000.00 | N/A |
| Revenue This Year | $124.03 | N/A |
| Revenue Next Year | $28.63 | $157.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $5.41 | $11.48 |
| 52 Week High | $12.49 | $50.19 |
Technical Indicators
Market Signals| Indicator | KURA | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 58.06 | 32.10 |
| Support Level | $8.09 | $11.48 |
| Resistance Level | $10.50 | $30.24 |
| Average True Range (ATR) | 0.39 | 0.92 |
| MACD | 0.09 | 0.12 |
| Stochastic Oscillator | 96.49 | 3.15 |
Price Performance
Historical Comparison KURA
LENZ
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.